SCHEMBL3989948

SCHEMBL3989948

c1ccc2c(c1)ccn2CCCN1CCCCC1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 4/20 0.71
▸ CCND1 P24385 4/20 0.71
▸ ABCB1 P08183 2/20 0.67
▸ SIGMAR1 Q99720 1/20 0.63
▸ DRD2 P14416 1/20 0.61
▸ DRD4 P21917 1/20 0.61
▸ DRD3 P35462 1/20 0.61
▸ P2RX7 Q99572 1/20 0.60
▸ FPR3 P25089 1/20 0.52
▸ HRH3 Q9Y5N1 2/20 0.51
▸ RAD52 P43351 1/20 0.50
▸ LMNA P02545 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ HTR2A P28223 1/20 0.49
▸ HTR2C P28335 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30102639 1.00 CDK4 (0.71) CDK4CCND1ABCB1SIGMAR1DRD2
SCHEMBL3989584 0.98 CDK4 (0.73) CDK4CCND1ABCB1SIGMAR1DRD2
SCHEMBL9776034 0.95 CDK4 (0.72) CDK4CCND1ABCB1SIGMAR1DRD2
SCHEMBL3990196 0.95 CDK4 (0.73) CDK4CCND1ABCB1SIGMAR1DRD2
SCHEMBL9776119 0.94 CDK4 (0.74) CDK4CCND1ABCB1SIGMAR1DRD2
SCHEMBL12543448 0.90 CDK4 (0.69) CDK4CCND1ABCB1SIGMAR1DRD2
SCHEMBL3990185 0.88 CDK4 (0.71) CDK4CCND1ABCB1SIGMAR1DRD2
SCHEMBL29780338 0.88 CDK4 (0.71) CDK4CCND1ABCB1SIGMAR1DRD2
SCHEMBL12605565 0.84 CDK4 (0.67) CDK4CCND1ABCB1SIGMAR1DRD2
SCHEMBL8471498 0.82 DRD2 (0.63) CDK4CCND1ABCB1SIGMAR1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943616-B2 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders AVENTIS PHARMACEUTICALS INC. (US) 2011-05-17 — — US disclosed
EP-2065382-A1 CGRP antagonists Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2009-06-03 — — EP disclosed
EP-2065382-A1 CGRP antagonists Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2009-06-03 — — EP disclosed
WO-2009050235-A1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-23 — — WO disclosed
Send feedback